Despite the size of the ever-growing inflammatory bowel disease (IBD) drug market and its diversity of modalities from JAK inhibitors to IL-23s, unmet needs and treatment gaps remain.
Read More
Market expectations for GLP-1 agonists have been high for some time. But in the past year, sales forecasts have gone stratospheric.
Read More
With biopharma pouring more money than ever into weight loss medicines, physicians would like to see improved GLP-1 drugs. But the goals of the two parties are not in full alignment, according to a new study from financing partner DNB Markets and strategic advisory firm Back Bay Life Science Advisors.
Read MoreBack Bay Named a Top Consulting Firm in the Country
Read More